Therapeutic Efficiency and Clinical Efficacy of Edaravone Combined with Rosuvastatin for Acute Cerebral Infarction Treatment
Objective To analyze the therapeutic efficiency and clinical efficacy of edaravone combined with rosuvas-tatin for the treatment of acute cerebral infarction.Methods A total of 186 patients with acute cerebral infarction ad-mitted to the Department of Neurology of Shouguang People's Hospital in Shandong Province from September 2020 to September 2023 were selected as the study objects,and were divided into single drug group and combined group by computer grouping method,with 93 cases in each group.On the basis of routine symptomatic support,the mono-therapy group was treated with rosuvastatin and the combination group was treated with edaravone combined with rosu-vastatin.The difference of curative effect between the two groups was compared.Results The effective rate of the com-bination group was 96.77%,significantly higher than that of the monotherapy group(88.17%),and the difference was statistically significant(χ2=4.944,P=0.026).Inflammatory factors,carotid intima-media thickness,plaque area,nerve function score and daily living ability score in combination group were significantly better than those in single drug group,and the difference was statistically significant(all P<0.05).No serious adverse reactions occurred during treat-ment.Conclusion The combination of Edaravone and rosuvastatin in the treatment of acute cerebral infarction is effec-tive,effective and safe.
万方数据
维普
